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Summary A questionnaire was sent to all centres in the UK involved in cryopreservation of semen from men
with malignant disease. Details were requested of samples stored from 1977 to 1987 and of successful use of
this sperm in subsequently achieving pregnancy. Twenty-two centres are involved and have stored specimens
from 2,219 men. There has been a three-fold increase in referrals in the past five years. Three regions in
England have no service. Twenty-seven pregnancies (21 live births) have been achieved in 22 couples.
Laboratories are poorly funded, making adequate record keeping and audit of the service difficult.
The price that many young men pay for the curative treat-
ment of malignant disease is infertility. It has been app-
reciated for many years that anti-cancer treatment may result
in azoospermia (Sutcliffe, 1987), which is frequently perma-
nent (Da Cunha et al., 1984). The damage to the testes
depends partly on the choice of drug - alkylating agents do
the most harm (Roeser et al., 1978; Miller, 1971) - and partly
on the duration of exposure (Waxman, 1985). Damage is
mainly confined to the germinal epithelium and Leydig cell
function is normal. This causes infertility but preserves libido
and potency.
The success of modern treatments for Hodgkin's disease,
non-Hodgkin's lymphoma and leukaemia has resulted in in-
creasing numbers of men who survive but who are infertile.
Some schedules for advanced germ cell tumours may also
cause infertility. Previous studies (Hendry et al., 1983) have
demonstrated that insemination with semen cryopreserved
before the start of chemotherapy may result in successful
pregnancy. Unfortunately many of these patients present
with low sperm counts or poorly motile sperm before treat-
ment starts (Sanger et al., 1980). Despite these limitations a
number of centres in the UK offer semen cryopreservation
for cancer patients. Although a single centre has published its
results (Hendry et al., 1983; Scammell et al., 1985) the prac-
tice throughout the UK has not been reviewed. We set out to
examine the availability of this service throughout the
country and to assess its success.
Methods
Postal questionnaires were sent to clinics and hospitals
throughout England, Wales, Scotland and Northern Ireland
notified to the Fertility Sub-committee of the Royal College
of Obstetricians and Gynaecologists. Some centres were not
recorded by this committee and questionnaires were sent to
them after informal enquiry. Where necessary, additional
information was obtained by telephone or further corres-
pondence. Respondents were asked to detail their experience
of semen cryopreservation in the period 1977-87. Details
were requested of the number of samples stored, the sperm
counts and motility and the underlying diagnosis. Inform-
ation about the success of stored semen in achieving preg-
nancy from 1977 to the present day was sought and in those
instances where pregnancy occurred, details of sperm quality
and insemination techniques were requested.
Results
The response was 100%. Twenty-two centres in the UK have
cryopreserved semen from 2,219 men with malignant disease
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(Table I). Hospitals vary widely in the number of patients
referred, the largest centres seeing five per month on average
and the smallest an occasional patient only. Over the past 5
years there has been a considerable increase in activity, the
number of new patients referred almost trebling when com-
pared with the first 5 years of the study. There was a wide
geographical difference in the availability of this service
throughout the country. Some regions (Oxford, Mersey and
Yorkshire) have no service and in East Anglia the service is
provided by the private sector but paid for by the NHS.
Facilities were provided roughly equally between NHS and
university departments. Although not specifically requested,
information gained informally suggested that specific funding
for this area was not set aside from Regional or District
Health Authority budgets. Many hospitals did not keep
accurate records of the primary diagnosis of the men referred
but when this was available the majority of the patients had
either germ cell tumours or advanced Hodgkin's disease. Not
all hospitals recorded when specimens with a low sperm
count or poor motility were rejected for storage but on
average 27% (range 0-53%) were considered unsuitable for
cryopreservation.
Artificial insemination
Twelve of the 22 hospitals have used frozen semen for
artifical insemination in 133 couples. Five of these 12 centres
have achieved successful pregnancies. There have been 27
pregnancies in 23 couples; these have ended in miscarriage on
six occasions and 21 normal deliveries. Further data were
collected on 18 of the pregnancies ending in live births.
Insemination was intracervical in all but two cases where
GIFT was used. The mean post-thaw sperm count was
55 x 106ml-' and the mean sperm motility was 39%. The
Table I Cryopreserved semen from men with malignant disease in the
United Kingdom 1977-87
Attempted
conception
Region No. stored (couples) Pregnancies Live births
Scotland 104 10 0 0
Northern Ireland 18 1 0 0
Wales 31 3 0 0
Londona 922 51 14 10
Northern 37 0 0 0
Trent 360 29 3 2
West Midlands 88 3 0 0
North Western 419 21 8 7
East Anglia 18 0 0 0
South West 172 13 2 2
Wessex 50 2 0 0
Total 2219 133 27 21
a All Thames regions.
Br. J. Cancer (1989), 60, 966-967 '." The Macmillan Press Ltd., 1989SEMEN CRYOPRESERVATION 967
lowest sperm count which achieved successful pregnancy was
10 x 106 ml' and the lowest motility was 20%. On average
3.4 cycles were needed to achieve pregnancy. Hormone
monitoring of the female cycle was used in all but three of
the 24 pregnancies where this information was available. In
two couples pregnancy was attempted by IVF but after
successful fertilisation of the ova there was failure of implan-
tation. The mean sperm storage time before successful preg-
nancy was 47 months, the maximum being 113 months.
Discussion
Despite the 100% response to the questionnaire the quality
of the information provided was frequently poor and the
results obtained can only offer a broad overview of current
practice in this country. We do feel that this is an important
area of debate and one that is all too easily overlooked in the
rush to confirm a diagnosis and start treatment. The develop-
ment of infertility is a heavy blow to many men undergoing
cytotoxic therapy for malignant disease. As the outlook for
some cancers has improved, the number of young patients
with infertility as a permanent consequence of treatment has
increased. Many doctors find this a difficult area to discuss,
especially when the patient is already burdened with the
impact of the primary diagnosis and the prospect of
chemotherapy. Frequently patients are too sick at presenta-
tion to permit collection of semen and there is a natural
tendency for the oncologists to wish to press on with treat-
ment as soon as possible. A common observation of res-
pondents to the questionnaire was that patients were referred
for semen storage rather as an afterthought and inadequate
time was allowed for semen collection.
This survey was conducted with a view to defining the
service that exists throughout the country but also to
examine which specimens were worth storing. Successful
pregnancies have generally been achieved using sperm with a
normal count and good motility. The majority ofpregnancies
have been aided by female hormone monitoring. The
development of new techniques of assisted conception (IVF
and GIFT) may allow successful pregnancy using semen of
poorer quality and at present it is difficult to define sperm
counts below which storage is not worthwhile but a realistic
target would be the presence of 5 x 106 motile sperm per ml.
This figure will need to be reviewed as skills in this area
increase. We consider that in order to avoid possible future
litigation semen cryopreservation should be offered to all
patients fulfilling these criteria when possible. The guidelines
recently suggested are very sensible (Selby et al., 1988). The
same authors have also highlighted the problems that may be
caused by the government white paper (Anon, 1987) on the
disposal of stored sperm. This suggests a maximum storage
time of 10 years. In this series two pregnancies occurred after
a storage time of 113 months and in future it is likely that
men will wish to use sperm that has been cryopreserved
longer than this. The Warnock Committee proposal of
regular review of all stored samples at 5-year intervals would
accommodate late conceptions but with adequate safeguards.
Overall the achievement of 21 live births when specimens
have been stored from in excess of 2,000 patients may seem
small. However, only 133 couples have been referred for
insemination. In the five hospitals where pregnancies occur-
red, about one-quarter of referred couples achieved a preg-
nancy. It was clear from analysis of the returns that many
laboratories had been established without specific funding to
carry out this work. As the referrals have increased it has
proved increasingly difficult to keep adequate records. Only
two departments had computerised record keeping. Many
laboratories had no formal system of identifying which
patients had died. Problems with record keeping also
extended to inadequate feedback information on the success
or otherwise of attempts at artificial insemination. For ins-
tance, one large laboratory was unable to provide data on
conceptions although it had stored 20% of the samples in the
UK.
In conclusion, it appears that semen cryopreservation is
effective for some young men with malignant disease. Ade-
quate funding and staffing of the departments undertaking
this work would allow for a much more effective audit of the
results, which would simplify exclusion criteria for sperm
storage and define optimum techniques of achieving preg-
nancy.
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